Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Assets (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Other Non-Current Assets data on record, last reported at $102000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 53.0% year-over-year to $102000.0; the TTM value through Dec 2025 reached $102000.0, down 53.0%, while the annual FY2025 figure was $102000.0, 53.0% down from the prior year.
  • Other Non-Current Assets reached $102000.0 in Q4 2025 per SNDX's latest filing, down from $217000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.0 million in Q1 2022 and bottomed at $102000.0 in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $279789.5, with a median of $217000.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: crashed 90.92% in 2021, then soared 793.04% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $115000.0 in 2021, then changed by 0.0% to $115000.0 in 2022, then skyrocketed by 88.7% to $217000.0 in 2023, then changed by 0.0% to $217000.0 in 2024, then plummeted by 53.0% to $102000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $102000.0 in Q4 2025, $217000.0 in Q3 2025, and $217000.0 in Q2 2025.